

Correction

Correction: Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy

Elisabetta Munzone¹ Giuseppe Curigliano¹, Andrea Rocca¹, Giuseppina Bonizzi², Giuseppe Renne³, Aron Goldhirsch¹ and Franco Nolè¹

¹Department of Medicine, Division of Medical Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy

²Department of Experimental Oncology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy

³Division of Pathology, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy

Published: 5 October 2006

Breast Cancer Research 2006, **8**:407 (doi:10.1186/bcr1606)

This article is online at <http://breast-cancer-research.com/content/8/5/407>

© 2006 BioMed Central Ltd

It has been brought to our attention that some paragraphs in the Introduction and Discussion of our recent research article [1] show close similarities to paragraphs in recent publications by Oh *et al.* [2] and Holloway *et al.* [3]. While these publications were referenced elsewhere in our paper, the paragraphs which show similarities were not specifically referenced.

We regret this and offer our apologies to the authors.

References

1. Munzone E, Curigliano G, Rocca A, Bonizzic G, Renne G, Goldhirsch A, Nolè F: **Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy.** *Breast Cancer Research* 2006, **8**:R4
2. Oh AS, Lorant LA, Holloway JN, Miller DL, Kern FG, El-Ashry D: **Hyperactivation of MAPK induces loss of ERα expression in breast cancer cells.** *Mol Endocrinol* 2001, **15**:1344–1359.
3. Holloway JN, Murthy S, El-Ashry D: **A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-down-regulation in breast cancer cells: the role of nuclear factor-B.** *Mol Endocrinol* 2004, **18**:1396–1410.